{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:50:24Z","timestamp":1773168624206,"version":"3.50.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec id=\"ab-ebr250007-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Apraclonidine, a topical \u03b1-2 adrenergic agonist, reverses anisocoria in patients with Horner syndrome, a disruption of the sympathetic chain to 1 eye and side of the face. In pediatric patients with anisocoria, apraclonidine is used off-label to exclude Horner syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify and characterize postmarketing case reports reported to the US Food and Drug Administration and reported in the medical literature of systemic toxicity in pediatric patients administered apraclonidine ophthalmic drops.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>A search of the US Food and Drug Administration\u2019s Adverse Event Reporting System and the medical literature was conducted from approval to September 18, 2024, for reports describing adverse events in pediatric patients who received apraclonidine ophthalmic drops. Participants included 21 children who developed systemic adverse events associated with use of apraclonidine ophthalmic drops. These data were analyzed from September 2024 to March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Apraclonidine ophthalmic drops.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-8\">\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>Reports describing nonsystemic adverse events, accidental oral ingestion, or duplicate reports for the same patient, and reports whose causal association with apraclonidine was unassessable, unclassifiable, or unlikely based on the World Health Organization\u2013Uppsala Monitoring Center system were excluded. The assessment included demographic information, reason for use, concomitant medications, dose, latency, medical intervention, and outcome information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This case series included 21 patients (aged 12 days to 6 years; median age, 6 months) who developed systemic adverse events associated with use of apraclonidine ophthalmic drops. The most commonly reported adverse event was prolonged lethargy and unresponsiveness (17 of 21 [81%]) followed by clinically significant cardiorespiratory events (eg, apnea, hypoxia, bradycardia, blood pressure changes, or respiratory failure) (8 of 21 [38%]). Three cases required intubation. Most cases (16 of 21 [76%]) described patients younger than 1 year. The reason for use in most (12 of 16 [75%]) patients younger than 1 year was for diagnostic purposes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ebr250007-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This case series suggests use of apraclonidine in pediatric patients poses a risk of central \u03b1-2 adrenergic agonist\u2013induced central nervous system and respiratory depression. Clinicians who use apraclonidine in the pediatric population should be aware of potential serious systemic effects from ophthalmic use of the drug and be prepared to manage these.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.4243","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:31:11Z","timestamp":1762446671000},"page":"1061","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients"],"prefix":"10.1001","volume":"143","author":[{"given":"Paula","family":"Gish","sequence":"first","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivone","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Christopher","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"ebr250007r1","first-page":"951","article-title":"Ocular effects of apraclonidine in Horner syndrome.","volume":"118","author":"Morales","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"ebr250007r4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"ebr250007r5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/IJG.0b013e31818624e5","article-title":"Exposure to topical apraclonidine in children with glaucoma.","volume":"18","author":"Wright","year":"2009","journal-title":"J Glaucoma"},{"issue":"3","key":"ebr250007r6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaapos.2007.02.015","article-title":"Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants.","volume":"11","author":"Watts","year":"2007","journal-title":"J AAPOS"},{"issue":"2","key":"ebr250007r7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/bja\/aeq183","article-title":"Systemic effects of topical ophthalmic agents.","volume":"105","author":"Yarwood","year":"2010","journal-title":"Br J Anaesth"},{"issue":"9","key":"ebr250007r8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/archopht.1987.01060090063028","article-title":"The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers.","volume":"105","author":"Abrams","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"ebr250007r9","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101711010305","article-title":"A single drop in the eye\u2014effects on the whole body?.","author":"Vaajanen","year":"2017","journal-title":"Open Ophthalmol J"},{"issue":"1","key":"ebr250007r10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/000992280404300114","article-title":"Systemic side effects of ophthalmic drops.","volume":"43","author":"Levy","year":"2004","journal-title":"Clin Pediatr (Phila)"},{"issue":"3","key":"ebr250007r12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ajo.2006.04.052","article-title":"Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination.","volume":"142","author":"Chen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"ebr250007r13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00055","article-title":"Apraclonidine is better than cocaine for detection of Horner syndrome.","author":"Bremner","year":"2019","journal-title":"Front Neurol"},{"issue":"3","key":"ebr250007r14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/WNO.0000000000002262","article-title":"Differentiation of Horner syndrome and physiological anisocoria by automated pupillometry.","volume":"45","author":"Disse","year":"2024","journal-title":"J Neuroophthalmol"},{"issue":"6","key":"ebr250007r15","doi-asserted-by":"publisher","first-page":"336.e1","DOI":"10.1016\/j.jaapos.2021.07.011","article-title":"Safety of apraclonidine eye drops in diagnosis of Horner syndrome in an outpatient pediatric ophthalmology clinic.","volume":"25","author":"Eldib","year":"2021","journal-title":"J AAPOS"},{"key":"ebr250007r2","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s Adverse Event Reporting System (FAERS). Accessed October 2, 2025. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"ebr250007r3","unstructured":"The Uppsala Monitoring Center. World Health Organization Uppsala Monitoring Centre system for standardized case causality assessment. Accessed October 2, 2025. https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf"},{"key":"ebr250007r11","unstructured":"AbbVie. Alphagan patient safety information. Accessed October 9, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021770s014,021262s028lbl.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2840926\/jamaophthalmology_gish_2025_br_250007_1765550228.14664.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:31Z","timestamp":1766073631000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2840926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.4243","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}